BR112015005351A2 - sistemas para distribuição de drogas e métodos para tratamento de disfunção de esvaziamento da bexiga e outros distúrbios do trato urinário inferior - Google Patents

sistemas para distribuição de drogas e métodos para tratamento de disfunção de esvaziamento da bexiga e outros distúrbios do trato urinário inferior

Info

Publication number
BR112015005351A2
BR112015005351A2 BR112015005351A BR112015005351A BR112015005351A2 BR 112015005351 A2 BR112015005351 A2 BR 112015005351A2 BR 112015005351 A BR112015005351 A BR 112015005351A BR 112015005351 A BR112015005351 A BR 112015005351A BR 112015005351 A2 BR112015005351 A2 BR 112015005351A2
Authority
BR
Brazil
Prior art keywords
bladder
methods
drug delivery
trospium
delivery systems
Prior art date
Application number
BR112015005351A
Other languages
English (en)
Inventor
Giesing Dennis
Original Assignee
Taris Biomedical Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taris Biomedical Llc filed Critical Taris Biomedical Llc
Publication of BR112015005351A2 publication Critical patent/BR112015005351A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Abstract

resumo “sistemas para distribuição de drogas e métodos para tratamento de disfunção de esvaziamento da bexiga e outros distúrbios do trato urinário inferior” métodos, dispositivos e medicamentos que incluem tróspio são fornecidos para uso no tratamento de disfunção da bexiga administrando localmente o tróspio na bexiga para atingir uma concentração sustentada de tróspio na urina na bexiga suficiente para produzir uma concentração terapêutica de tróspio no tecido da bexiga. a droga pode ser distribuída para a bexiga de um dispositivo de distribuição de droga intravesical inserido na bexiga, em que o dispositivo libera continuamente a droga para a urina na bexiga durante um período prolongado de horas ou dias.
BR112015005351A 2012-09-18 2013-09-18 sistemas para distribuição de drogas e métodos para tratamento de disfunção de esvaziamento da bexiga e outros distúrbios do trato urinário inferior BR112015005351A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261702576P 2012-09-18 2012-09-18
PCT/US2013/060479 WO2014047221A1 (en) 2012-09-18 2013-09-18 Drug delivery systems and methods for treatment of bladder voiding dysfunction|and other lower urinary tract disorders by using trospium

Publications (1)

Publication Number Publication Date
BR112015005351A2 true BR112015005351A2 (pt) 2017-07-04

Family

ID=49301639

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015005351A BR112015005351A2 (pt) 2012-09-18 2013-09-18 sistemas para distribuição de drogas e métodos para tratamento de disfunção de esvaziamento da bexiga e outros distúrbios do trato urinário inferior

Country Status (13)

Country Link
US (2) US10500200B2 (pt)
EP (1) EP2897616A1 (pt)
JP (2) JP6600256B2 (pt)
KR (1) KR102141433B1 (pt)
CN (2) CN104684556A (pt)
AU (1) AU2013318146B2 (pt)
BR (1) BR112015005351A2 (pt)
CA (1) CA2883855C (pt)
IL (1) IL237498B (pt)
MX (2) MX2015003110A (pt)
RU (1) RU2670749C9 (pt)
SG (1) SG11201502104YA (pt)
WO (1) WO2014047221A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8721621B2 (en) 2009-09-10 2014-05-13 Taris Biomedical, Inc. Systems and methods for deploying devices to genitourinary sites
PL2890384T3 (pl) 2012-08-31 2022-02-14 Taris Biomedical Llc Układy podawania leku i sposoby leczenia raka pęcherza obejmujące oksaliplatynę
BR112015004110A2 (pt) 2012-08-31 2017-07-04 Taris Biomedical Llc sistemas e métodos de distribuição de drogas para tratamento de próstata
CN104684556A (zh) * 2012-09-18 2015-06-03 塔里斯生物医药公司 通过使用曲司铵来治疗膀胱排尿功能障碍和其它下泌尿道病症的药物递送系统和方法
EP3597176A1 (en) 2014-08-19 2020-01-22 The Regents Of The University Of California Implants for localized drug delivery and methods of use thereof
GB201506526D0 (en) 2015-04-17 2015-06-03 Uropharma Ltd And Synesis Llc Medicinal composition
CN106706832A (zh) * 2015-08-06 2017-05-24 舒泰神（北京）生物制药股份有限公司 一种测定曲司氯铵含量的方法
HUE054587T2 (hu) * 2017-02-01 2021-09-28 Taris Biomedical Llc In vivo gyógyszerbejuttató eszközök
WO2020028554A1 (en) * 2018-08-01 2020-02-06 Taris Biomedical Llc Methods of treating overactive bladder using trospium
WO2020222139A1 (en) * 2019-04-30 2020-11-05 Trigone Pharma Ltd. Formulations and methods for drug instillation into the bladder and treatment of bladder ailments
US11338119B2 (en) 2020-03-20 2022-05-24 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
US11173291B2 (en) 2020-03-20 2021-11-16 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
US11344526B2 (en) 2020-03-20 2022-05-31 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
KR102596697B1 (ko) 2021-05-20 2023-11-01 김정우 바위솔 추출물을 유효성분으로 포함하는 화장품 조성물 및 그 제조 방법

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2125696T3 (es) * 1996-11-27 1999-03-01 Pfleger R Chem Fab Utilizacion del cloruro de tropsio para la produccion de una preparacion farmaceutica para el tratamiento de disfunciones vesicales.
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
AU2003286129A1 (en) * 2002-12-11 2004-06-30 Coloplast A/S A urinary catheter device with a pharmaceutically active composition
WO2004064789A2 (en) 2003-01-16 2004-08-05 University Of Rochester Quaternary antimuscarinic compounds for the treatment of bladder diseases
ES2322148T3 (es) 2004-08-11 2009-06-17 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Medicamentos que contienen anticolinergicos para el tratamiento en las vias urinarias.
WO2006101954A2 (en) * 2005-03-17 2006-09-28 Indevus Pharmaceuticals, Inc. Interstitial cystitis treatment
US7390816B2 (en) 2005-06-21 2008-06-24 Bridge Pharma, Inc. Methods for treating urinary incontinence in patients suffering from memory disorders
DK1933810T3 (da) 2005-08-11 2013-01-28 Childrens Medical Center Intravesikal lægemiddelafgivelsesindretning og fremgangsmåde
US20100003297A1 (en) 2005-08-11 2010-01-07 Massachusetts Institute Of Technology Implantable Drug Delivery Device and Methods of Treating Male Genitourinary and Surrounding Tissues
EP1967202A1 (en) 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
JP5560200B2 (ja) 2007-12-11 2014-07-23 マサチューセッツ インスチテュート オブ テクノロジー 膀胱および他の身体の小嚢又は管腔を治療するための埋め込み型薬物供給デバイス
AU2010265866B2 (en) 2009-06-26 2012-07-12 Taris Biomedical Llc Solid drug tablets for implantable drug delivery devices
US8721621B2 (en) 2009-09-10 2014-05-13 Taris Biomedical, Inc. Systems and methods for deploying devices to genitourinary sites
US9017312B2 (en) 2009-09-10 2015-04-28 Taris Biomedical Llc Implantable device for controlled drug delivery
DK2512581T3 (da) 2009-12-17 2021-03-29 Taris Biomedical Llc Implanterbar indretning med intravesikal tolerance
US20110218488A1 (en) 2010-03-05 2011-09-08 Taris Biomedical, Inc. Systems and Methods for Implanting Devices in the Bladder and Other Genitourinary Sites
WO2012048104A1 (en) 2010-10-06 2012-04-12 Taris Biomedical, Inc. Implantable drug delivery device with bladden retention feature
JP5945544B2 (ja) * 2010-10-06 2016-07-05 タリス バイオメディカル エルエルシー 時間選択的に生体吸収可能または崩壊可能な薬剤送達システムおよび方法
AU2012205654B2 (en) 2011-01-10 2016-09-08 Allergan, Inc. Lidocaine regimen for the use of sustained treatment of bladder pain and irritative voiding
US9107816B2 (en) * 2011-02-04 2015-08-18 Taris Biomedical Llc Implantable device for controlled dissolution and diffusion of low solubility drug
CN104684556A (zh) * 2012-09-18 2015-06-03 塔里斯生物医药公司 通过使用曲司铵来治疗膀胱排尿功能障碍和其它下泌尿道病症的药物递送系统和方法
NZ711546A (en) 2013-03-15 2017-12-22 Taris Biomedical Llc Drug delivery devices with drug-permeable component and methods

Also Published As

Publication number Publication date
WO2014047221A1 (en) 2014-03-27
US10500200B2 (en) 2019-12-10
CA2883855A1 (en) 2014-03-27
RU2670749C9 (ru) 2018-12-13
AU2013318146B2 (en) 2018-05-10
RU2015112196A (ru) 2016-11-10
WO2014047221A9 (en) 2015-05-21
MX2020002465A (es) 2020-07-13
JP2015529688A (ja) 2015-10-08
MX2015003110A (es) 2015-06-05
KR20150058271A (ko) 2015-05-28
JP6600256B2 (ja) 2019-10-30
US20150182516A1 (en) 2015-07-02
US11850244B2 (en) 2023-12-26
JP2018080208A (ja) 2018-05-24
US20200108057A1 (en) 2020-04-09
RU2670749C2 (ru) 2018-10-25
CA2883855C (en) 2020-09-15
AU2013318146A1 (en) 2015-03-19
EP2897616A1 (en) 2015-07-29
CN111450093A (zh) 2020-07-28
IL237498B (en) 2018-01-31
IL237498A0 (en) 2015-04-30
KR102141433B1 (ko) 2020-08-05
SG11201502104YA (en) 2015-05-28
CN104684556A (zh) 2015-06-03

Similar Documents

Publication Publication Date Title
BR112015005351A2 (pt) sistemas para distribuição de drogas e métodos para tratamento de disfunção de esvaziamento da bexiga e outros distúrbios do trato urinário inferior
BR112015004110A2 (pt) sistemas e métodos de distribuição de drogas para tratamento de próstata
BR112015003836A2 (pt) sistemas e métodos para distribuição de drogas para tratamento de câncer de bexiga
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
MX352824B (es) Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado común e inflamación.
EA201290171A1 (ru) Вводимые перорально кортикостероидные композиции
EA202091999A2 (ru) Применение ингибиторов dpp iv
MX2013013809A (es) Dispositivos expandibles con revestimiento de una composicion de paclitaxel.
MX2011007589A (es) Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.
BR112015018252A2 (pt) composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano, composição de suspensão aquosa farmacêutica de dose fixa estável para administração nasal para um ser humano, suspensão estável adequada para administração nasal a um ser humano, método para tratar rinite em um ser humano necessitando do mesmo, uso da composição farmacêutica para administração nasal, método para liberar uma composição farmacêutica e kit
AR082312A1 (es) Una composicion farmaceutica de combinacion para tratar diabetes y desordenes metabolicos
EP3300734A3 (en) Use of levocetirizine and montelukast in the treatment of autoimmune disorders
MY193694A (en) Membrane-adherent self-assembled systems for treatment of ocular disorders
MX2018013715A (es) Composiciones acuosas de capsaicinoides que comprenden un analgesico y un vehiculo acuoso, y uso de las mismas para el tratamiento del dolor.
MX2013008175A (es) Composiciones farmacéuticas para suministro tópico de fotosensibilizadores y usos de los mismos.
EA201491702A1 (ru) Оптимизированные терапевтические агенты для подкожного введения
MX2016006179A (es) Formulaciones de capsaicinoides basadas en agua y metodos de manufactura y uso.
MX2013013808A (es) Dispositivos expandibles con revestimiento de una composicion de rapamicina.
AR079000A1 (es) Terapia anticancerosa dirigida a celulas madre cancerosas resistentes a las drogas
MX2010006724A (es) Regimenes terapeuticos para el tratamiento de desordenes inmunoinflamatorios.
MY180772A (en) Novel therapeutic mirtazapine combinations for use in pain disorders
UA109359C2 (xx) Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
Barsotti CMV lung infection, bladder infection and erythematous rash: 3 case reports
RU2008130241A (ru) Способ и средство для реабилитации детей с хроническими риносинуситами
Ali Al-Beer et al. Effectiveness of Non Steroidal Anti Inflamatery Drug

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]